Comparison of Antibody Levels in Response to SARS-CoV-2 Infection and Vaccination Type in a Midwestern Cohort

We present preliminary data in an ongoing observational study reporting SARS-CoV-2 spike protein reactive antibody levels from a convenience cohort of over 250 individuals in Kansas City. We observe stable antibody levels over one year in individuals who recovered from COVID19 infection caused by SARS-CoV-2. By comparison, our data reveals even higher antibody levels from naïve individuals vaccinated with Pfizer or Moderna vaccines and slightly lower levels from Johnson & Johnson (J&J) recipients. For all vaccines, inoculation after recovery resulted in higher antibody levels than vaccination alone. Responses to Pfizer and Moderna vaccines decreased over time from high initial levels but at the time of publication remain higher than those for recovered or J&J recipients. Within our limited cohort we only see slight demographic trends including higher antibody levels in recovered female vs. male individuals. Booster doses and breakthrough infections both result in rapid increases in antibody levels.